Lipocine Stock Price, News & Analysis (NASDAQ:LPCN)

$1.34 -0.09 (-6.29 %)
(As of 01/19/2018 02:24 PM ET)
Previous Close$1.43
Today's Range$1.30 - $1.44
52-Week Range$1.40 - $5.33
Volume902,787 shs
Average Volume1.64 million shs
Market Capitalization$28.62 million
P/E Ratio-1.40
Dividend YieldN/A
Beta0.11

About Lipocine (NASDAQ:LPCN)

Lipocine logoLipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company's additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip'ral promicellar drug delivery technology platform. Lip'ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.

Receive LPCN News and Ratings via Email

Sign-up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:LPCN
CUSIPN/A
Phone+1-801-9947383

Debt

Debt-to-Equity RatioN/A
Current Ratio10.54%
Quick Ratio10.54%

Price-To-Earnings

Trailing P/E Ratio-1.39583333333333
Forward P/E Ratio-1.29
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.42 per share
Price / Book0.94

Profitability

Trailing EPS($0.96)
Net Income$-18,970,000.00
Net MarginsN/A
Return on Equity-74.63%
Return on Assets-68.41%

Miscellaneous

Employees14
Outstanding Shares21,200,000

Lipocine (NASDAQ:LPCN) Frequently Asked Questions

What is Lipocine's stock symbol?

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

How were Lipocine's earnings last quarter?

Lipocine Inc (NASDAQ:LPCN) posted its quarterly earnings results on Wednesday, November, 8th. The specialty pharmaceutical company reported ($0.22) EPS for the quarter, beating the Zacks' consensus estimate of ($0.27) by $0.05. View Lipocine's Earnings History.

When will Lipocine make its next earnings announcement?

Lipocine is scheduled to release their next quarterly earnings announcement on Monday, March, 5th 2018. View Earnings Estimates for Lipocine.

Where is Lipocine's stock going? Where will Lipocine's stock price be in 2018?

4 brokerages have issued 12-month target prices for Lipocine's shares. Their forecasts range from $2.00 to $38.00. On average, they anticipate Lipocine's share price to reach $13.50 in the next year. View Analyst Ratings for Lipocine.

Who are some of Lipocine's key competitors?

Who are Lipocine's key executives?

Lipocine's management team includes the folowing people:

  • Mahesh V. Patel Ph.D., Chairman of the Board, President, Chief Executive Officer (Age 57)
  • Morgan R. Brown CPA, Chief Financial Officer, Executive Vice President (Age 47)
  • Gregory Bass, Executive Vice President, Chief Commercial Officer
  • Stephen Anthony Hill M.D., Lead Independent Director (Age 59)
  • Jeffrey A. Fink, Director (Age 57)
  • Richard Dana Ono, Director (Age 62)
  • John W. Higuchi, Non-Executive Director (Age 47)

How do I buy Lipocine stock?

Shares of Lipocine can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lipocine's stock price today?

One share of Lipocine stock can currently be purchased for approximately $1.43.

How big of a company is Lipocine?

Lipocine has a market capitalization of $28.62 million. The specialty pharmaceutical company earns $-18,970,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis. Lipocine employs 14 workers across the globe.

How can I contact Lipocine?

Lipocine's mailing address is 675 S Arapeen Dr Ste 202, SALT LAKE CITY, UT 84108-1295, United States. The specialty pharmaceutical company can be reached via phone at +1-801-9947383 or via email at [email protected]


MarketBeat Community Rating for Lipocine (LPCN)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  147 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  220
MarketBeat's community ratings are surveys of what our community members think about Lipocine and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Lipocine (NASDAQ:LPCN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.753.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $13.50$19.67$24.67$24.33
Price Target Upside: 621.93% upside470.05% upside470.99% upside473.90% upside

Lipocine (NASDAQ:LPCN) Consensus Price Target History

Price Target History for Lipocine (NASDAQ:LPCN)

Lipocine (NASDAQ:LPCN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/12/2018HC WainwrightSet Price TargetBuy -> Buy$10.00 -> $3.00HighView Rating Details
1/11/2018Ladenburg Thalmann Financial ServicesReiterated RatingBuy$11.00HighView Rating Details
1/11/2018Canaccord GenuityDowngradeBuy -> HoldHighView Rating Details
8/10/2017Roth CapitalSet Price TargetBuy$38.00MediumView Rating Details
(Data available from 1/19/2016 forward)

Earnings

Lipocine (NASDAQ:LPCN) Earnings History and Estimates Chart

Earnings by Quarter for Lipocine (NASDAQ:LPCN)

Lipocine (NASDAQ LPCN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/5/2018($0.21)N/AView Earnings Details
11/8/2017Q3 2017($0.27)($0.22)ViewN/AView Earnings Details
8/7/2017Q2 2017($0.30)($0.31)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.30)($0.26)ViewN/AView Earnings Details
3/6/2017Q4 2016($0.28)($0.16)ViewN/AView Earnings Details
11/8/2016Q3 2016($0.30)($0.16)ViewN/AView Earnings Details
8/9/2016Q2($0.37)($0.32)ViewN/AView Earnings Details
5/9/2016Q1($0.33)($0.38)ViewN/AView Earnings Details
3/10/2016Q4 2015($0.29)($0.25)ViewN/AView Earnings Details
11/12/2015Q3($0.35)($0.35)ViewN/AView Earnings Details
8/11/2015Q2 2015($0.20)($0.26)ViewN/AView Earnings Details
5/7/2015Q1 2015($0.35)($0.23)ViewN/AView Earnings Details
3/11/2015Q4 2014($0.35)($0.32)ViewN/AView Earnings Details
11/10/2014Q3 2014($0.58)($0.32)ViewN/AView Earnings Details
8/13/2014Q2 2014($0.42)($0.55)ViewN/AView Earnings Details
5/13/2014Q1 2014($0.35)($0.41)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Lipocine (NASDAQ:LPCN) Earnings Estimates

2018 EPS Consensus Estimate: ($0.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.82$0.82$0.82
Q2 20181($0.32)($0.32)($0.32)
Q3 20181($0.35)($0.35)($0.35)
Q4 20181($0.39)($0.39)($0.39)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Lipocine (NASDAQ:LPCN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Lipocine (NASDAQ LPCN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.30%
Institutional Ownership Percentage: 22.06%
Insider Trades by Quarter for Lipocine (NASDAQ:LPCN)
Institutional Ownership by Quarter for Lipocine (NASDAQ:LPCN)

Lipocine (NASDAQ LPCN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/29/2018Gregory Brooks BassInsiderSell3,750$3.47$13,012.509,375View SEC Filing  
12/29/2018Mahesh V PatelCEOSell6,000$3.48$20,880.00728,112View SEC Filing  
12/29/2018Morgan R BrownCFOSell2,813$3.47$9,761.1126,375View SEC Filing  
12/29/2018Stephen A HillDirectorSell1,250$3.47$4,337.506,500View SEC Filing  
12/29/2017Gregory Brooks BassInsiderSell3,750$3.47$13,012.50View SEC Filing  
12/29/2017Jeffrey Arvin FinkDirectorSell938$3.47$3,254.86View SEC Filing  
12/29/2017Mahesh V PatelCEOSell6,000$3.48$20,880.00View SEC Filing  
12/29/2017Morgan R BrownCFOSell2,813$3.47$9,761.11View SEC Filing  
9/30/2015John W HiguchiDirectorBuy5,000$12.68$63,400.00693,382View SEC Filing  
9/30/2015Mahesh V. PatelCEOBuy4,000$11.84$47,360.00887,632View SEC Filing  
11/25/2014Mahesh V PatelCEOBuy2,000$5.10$10,200.00View SEC Filing  
11/24/2014Mahesh V PatelCEOBuy2,000$5.45$10,900.00View SEC Filing  
11/19/2014Richard Dana OnoDirectorBuy4,000$5.14$20,560.00View SEC Filing  
11/14/2014Mahesh V PatelCEOBuy2,000$5.06$10,120.00View SEC Filing  
11/13/2014Mahesh V PatelCEOBuy2,000$5.05$10,100.00View SEC Filing  
11/13/2014Stephen A HillDirectorBuy4,000$4.95$19,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Lipocine (NASDAQ LPCN) News Headlines

Source:
DateHeadline
HC Wainwright Reiterates "$3.00" Price Target for Lipocine (LPCN)HC Wainwright Reiterates "$3.00" Price Target for Lipocine (LPCN)
www.americanbankingnews.com - January 14 at 12:38 AM
Zacks: Analysts Set $9.00 Target Price for Lipocine Inc (LPCN)Zacks: Analysts Set $9.00 Target Price for Lipocine Inc (LPCN)
www.americanbankingnews.com - January 13 at 1:38 AM
LIPOCINE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lipocine, Inc. To Contact The FirmLIPOCINE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lipocine, Inc. To Contact The Firm
finance.yahoo.com - January 12 at 5:13 PM
Lipocines Oral Testosterone Drug Fails To Win FDA Panel BackingLipocine's Oral Testosterone Drug Fails To Win FDA Panel Backing
www.nasdaq.com - January 12 at 9:31 AM
Pre-Open Movers 01/11: (SECO) (NBEV) (MGI) Higher; (LPCN) (HMNY) (APPN) Lower (more...)Pre-Open Movers 01/11: (SECO) (NBEV) (MGI) Higher; (LPCN) (HMNY) (APPN) Lower (more...)
www.streetinsider.com - January 11 at 5:32 PM
Adcom Outcome For Lipcocines Testosterone Drug Punctures Stock; Canaccord DowngradesAdcom Outcome For Lipcocine's Testosterone Drug Punctures Stock; Canaccord Downgrades
www.benzinga.com - January 11 at 5:32 PM
After-Hours Stock Movers 01/10: (PRGS) (MFIN) (KBH) Higher; (LPCN) (ARDM) Lower (more...)After-Hours Stock Movers 01/10: (PRGS) (MFIN) (KBH) Higher; (LPCN) (ARDM) Lower (more...)
www.streetinsider.com - January 11 at 9:43 AM
What’s Next For Lipocine After A Disappointing Panel Review?What’s Next For Lipocine After A Disappointing Panel Review?
finance.yahoo.com - January 11 at 9:43 AM
Ladenburg Thalmann Financial Services Reaffirms "Buy" Rating for Lipocine (LPCN)Ladenburg Thalmann Financial Services Reaffirms "Buy" Rating for Lipocine (LPCN)
www.americanbankingnews.com - January 11 at 8:38 AM
BRIEF-Lipocine Says FDAs BRUDAC Voted 6 In Favor & 13 Against Benefit/Risk Profile Of TlandoBRIEF-Lipocine Says FDA's BRUDAC Voted 6 In Favor & 13 Against Benefit/Risk Profile Of Tlando
www.reuters.com - January 10 at 5:22 PM
Lipocine Announces Outcome of FDA Advisory Committee Meeting for TLANDO™, Testosterone Replacement Therapy in Adult Males with HypogonadismLipocine Announces Outcome of FDA Advisory Committee Meeting for TLANDO™, Testosterone Replacement Therapy in Adult Males with Hypogonadism
finance.yahoo.com - January 10 at 5:22 PM
Lipocine Inc (LPCN) Fails to Convince FDA Committee of TLANDO’s Merit; Shares Decline Over 50%Lipocine Inc (LPCN) Fails to Convince FDA Committee of TLANDO’s Merit; Shares Decline Over 50%
finance.yahoo.com - January 10 at 5:22 PM
 Analysts Anticipate Lipocine Inc (LPCN) to Post -$0.26 EPS Analysts Anticipate Lipocine Inc (LPCN) to Post -$0.26 EPS
www.americanbankingnews.com - January 4 at 3:26 PM
Lipocine Anticipating Results from Two Near Term FDA Dates, PDUFA and BRUDACLipocine Anticipating Results from Two Near Term FDA Dates, PDUFA and BRUDAC
finance.yahoo.com - January 4 at 9:23 AM
Lipocine Inc (LPCN) Insider Gregory Brooks Bass Sells 3,750 SharesLipocine Inc (LPCN) Insider Gregory Brooks Bass Sells 3,750 Shares
www.americanbankingnews.com - January 3 at 1:00 AM
Mahesh V. Patel Sells 6,000 Shares of Lipocine Inc (LPCN) StockMahesh V. Patel Sells 6,000 Shares of Lipocine Inc (LPCN) Stock
www.americanbankingnews.com - January 3 at 1:00 AM
Lipocine Inc (LPCN) CEO Mahesh V. Patel Sells 6,000 SharesLipocine Inc (LPCN) CEO Mahesh V. Patel Sells 6,000 Shares
www.americanbankingnews.com - January 3 at 12:58 AM
Attention Biotech Investors: Brace For These January PDUFA Events - BenzingaAttention Biotech Investors: Brace For These January PDUFA Events - Benzinga
www.benzinga.com - December 30 at 5:16 PM
Zacks: Analysts Set $11.33 Target Price for Lipocine Inc (LPCN)Zacks: Analysts Set $11.33 Target Price for Lipocine Inc (LPCN)
www.americanbankingnews.com - December 29 at 5:52 AM
Zacks: Brokerages Anticipate Lipocine Inc (LPCN) to Post -$0.26 EPSZacks: Brokerages Anticipate Lipocine Inc (LPCN) to Post -$0.26 EPS
www.americanbankingnews.com - December 19 at 1:24 AM
HC Wainwright Reaffirms Buy Rating for Lipocine (LPCN)HC Wainwright Reaffirms Buy Rating for Lipocine (LPCN)
www.americanbankingnews.com - December 8 at 8:48 AM
Zacks: Lipocine Inc (LPCN) Given Average Recommendation of "Strong Buy" by BrokeragesZacks: Lipocine Inc (LPCN) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - December 8 at 3:50 AM
Lipocine Inc. (LPCN) Expected to Announce Earnings of -$0.27 Per ShareLipocine Inc. (LPCN) Expected to Announce Earnings of -$0.27 Per Share
www.americanbankingnews.com - November 30 at 11:22 PM
LPCN: Third Quarter Operational and Financial ResultsLPCN: Third Quarter Operational and Financial Results
finance.yahoo.com - November 23 at 6:13 AM
U.S. FDA Extends Review for TLANDO™; Advisory Committee Meeting Date of January 10, 2018 Remains UnchangedU.S. FDA Extends Review for TLANDO™; Advisory Committee Meeting Date of January 10, 2018 Remains Unchanged
finance.yahoo.com - November 17 at 2:09 PM
Zacks: Analysts Expect Lipocine Inc. (LPCN) to Post -$0.27 Earnings Per ShareZacks: Analysts Expect Lipocine Inc. (LPCN) to Post -$0.27 Earnings Per Share
www.americanbankingnews.com - November 12 at 11:10 AM
Lipocine Announces Financial and Operational Results for the Third ... - GlobeNewswire (press release)Lipocine Announces Financial and Operational Results for the Third ... - GlobeNewswire (press release)
globenewswire.com - November 8 at 2:52 PM
Lipocine Announces Financial and Operational Results for the Third Quarter and Nine Months Ended September 30, 2017Lipocine Announces Financial and Operational Results for the Third Quarter and Nine Months Ended September 30, 2017
finance.yahoo.com - November 8 at 2:52 PM
Lipocine reports 3Q lossLipocine reports 3Q loss
finance.yahoo.com - November 8 at 2:52 PM
Contrasting Lipocine (LPCN) and The CompetitionContrasting Lipocine (LPCN) and The Competition
www.americanbankingnews.com - November 3 at 1:10 PM
Financial Contrast: Lipocine (LPCN) & Its PeersFinancial Contrast: Lipocine (LPCN) & Its Peers
www.americanbankingnews.com - October 31 at 8:58 AM
Lipocine Inc. (LPCN) to Release Quarterly Earnings on MondayLipocine Inc. (LPCN) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 1:50 PM
Lipocine (LPCN) Says FDA Advisory Committee is Scheduled to Review TLANDO on January 10Lipocine (LPCN) Says FDA Advisory Committee is Scheduled to Review TLANDO on January 10
www.streetinsider.com - October 20 at 5:28 AM
Lipocine (LPCN) Says FDA Advisory Committee is Scheduled to Review TLANDO on January 10 - StreetInsider.comLipocine (LPCN) Says FDA Advisory Committee is Scheduled to Review TLANDO on January 10 - StreetInsider.com
www.streetinsider.com - October 18 at 3:26 PM
FDA Advisory Committee Scheduled to Review TLANDO™ on January 10, 2018FDA Advisory Committee Scheduled to Review TLANDO™ on January 10, 2018
finance.yahoo.com - October 18 at 3:26 PM
Lipocine: Playing The PDUFA Runup - Seeking AlphaLipocine: Playing The PDUFA Runup - Seeking Alpha
seekingalpha.com - October 15 at 7:21 PM
Analyzing Lipocine (LPCN) & Its CompetitorsAnalyzing Lipocine (LPCN) & Its Competitors
www.americanbankingnews.com - October 15 at 6:26 AM
Stocks Under Scanner in the Generic Drugs Space -- Akorn, Pacira Pharma, Rigel Pharma, and Lipocine - PR Newswire (press release)Stocks Under Scanner in the Generic Drugs Space -- Akorn, Pacira Pharma, Rigel Pharma, and Lipocine - PR Newswire (press release)
www.prnewswire.com - September 26 at 5:52 PM
Stocks Under Scanner in the Generic Drugs Space -- Akorn, Pacira Pharma, Rigel Pharma, and LipocineStocks Under Scanner in the Generic Drugs Space -- Akorn, Pacira Pharma, Rigel Pharma, and Lipocine
www.bizjournals.com - September 26 at 9:27 AM
LPCN: Advisory Committee Required and USPTO Issues Motion for TlandoLPCN: Advisory Committee Required and USPTO Issues Motion for Tlando
finance.yahoo.com - September 23 at 6:08 AM
FDA Nod For ABMD, AERI Faces FDA Panel In Oct, IPCI Put On Notice, PFE Sues JNJFDA Nod For ABMD, AERI Faces FDA Panel In Oct, IPCI Put On Notice, PFE Sues JNJ
www.rttnews.com - September 22 at 11:06 AM
Lipocine (LPCN) Announces FDA Advisory Committee Meeting for TLANDO - StreetInsider.comLipocine (LPCN) Announces FDA Advisory Committee Meeting for TLANDO - StreetInsider.com
www.streetinsider.com - September 21 at 4:20 PM
Lipocine Announces Motions Decision by USPTO in Interference Against Clarus - GlobeNewswire (press release)Lipocine Announces Motions Decision by USPTO in Interference Against Clarus - GlobeNewswire (press release)
globenewswire.com - September 21 at 4:20 PM
Lipocine Announces FDA Advisory Committee Meeting for TLANDO™Lipocine Announces FDA Advisory Committee Meeting for TLANDO™
finance.yahoo.com - September 21 at 4:20 PM
Lipocine Announces Motions Decision by USPTO in Interference Against ClarusLipocine Announces Motions Decision by USPTO in Interference Against Clarus
finance.yahoo.com - September 21 at 4:20 PM
Lipocine to Present at the Ladenburg Thalmann 2017 Healthcare ConferenceLipocine to Present at the Ladenburg Thalmann 2017 Healthcare Conference
finance.yahoo.com - September 20 at 2:51 AM
Lipocine (LPCN) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowLipocine (LPCN) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 7:20 AM
Lipocine to Present at the Rodman & Renshaw 19th Annual Global Investment ConferenceLipocine to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - September 5 at 4:13 PM
Lipocine Inc. (LPCN) Expected to Post Earnings of -$0.31 Per ShareLipocine Inc. (LPCN) Expected to Post Earnings of -$0.31 Per Share
www.americanbankingnews.com - August 28 at 10:28 AM
Daily Technical Summary Reports on Generic Drugs Stocks -- Collegium Pharma, Momenta Pharma, Lipocine, and Diplomat PharmaDaily Technical Summary Reports on Generic Drugs Stocks -- Collegium Pharma, Momenta Pharma, Lipocine, and Diplomat Pharma
www.bizjournals.com - August 24 at 8:49 AM

SEC Filings

Lipocine (NASDAQ:LPCN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Lipocine (NASDAQ:LPCN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Lipocine (NASDAQ LPCN) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.